[Capivasertib in combination with fulvestrant in locally advanced or metastatic RH+ HER2- breast cancer with PIK3CA, AKT1 or PTEN alteration, after first-line hormonal therapy]

Victor Heurtier; Alexandre de Nonneville

doi:10.1016/j.bulcan.2024.08.010

[Capivasertib in combination with fulvestrant in locally advanced or metastatic RH+ HER2- breast cancer with PIK3CA, AKT1 or PTEN alteration, after first-line hormonal therapy]

Bull Cancer. 2024 Nov;111(11):997-998. doi: 10.1016/j.bulcan.2024.08.010. Epub 2024 Sep 23.

[Article in French]

Authors

Victor Heurtier¹, Alexandre de Nonneville²

Affiliations

¹ Unité de génétique clinique, institut Curie, Sorbonne université, Paris, France. Electronic address: victor.heurtier@gmail.com.
² Institut Paoli-Calmettes, CRCM, CNRS, Inserm, Aix-Marseille université, Marseille, France.

PMID: 39317592
DOI: 10.1016/j.bulcan.2024.08.010

No abstract available

Keywords: AKT inhibitor; Breast cancer; Cancer du sein; Capivasertib; Hormonal receptor positive (HR+); ITK; Récepteur hormonal positif (RH+); TKI; Targeted therapy; Thérapie ciblée; inhibiteur d’AKT.

Publication types

Letter